

Editorial

Phase II Cancer Trials: Out of Control?

□□ *Commentary on Michaelis et al., p. 2400*

Bruce Chabner2307

The Biology Behind

The Use of Epigenetic Biomarkers for Preclinical Detection of Hepatocellular Carcinoma: Potential for Noninvasive Screening of High-Risk Populations.

□□ *Commentary on Zhang et al., p. 2378*

Ashley G. Rivenbark and William B. Coleman2309

Molecular Pathways

Targeting TRAIL Agonistic Receptors for Cancer Therapy.

Carmelo Carlo-Stella,
Cristiana Lavazza, Alberta Locatelli, Lucia Viganò, Alessandro M. Gianni, and Luca Gianni

.....2313

Report From the FDA

Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma.

Bhupinder S. Mann, John R. Johnson, Kun He, Rajeshwari Sridhara,
Sophia Abraham, Brian P. Booth, Leigh Verbois, David E. Morse, Josephine M. Jee, Sarah Pope,
Ravi S. Harapanhalli, Ramzi Dagher, Ann Farrell, Robert Justice, and Richard Pazdur

.....2318

Human Cancer Biology

Higher Frequency of Diploidy in Young-Onset Microsatellite-Stable Colorectal Cancer.

Lisa A. Boardman, Ruth A. Johnson, Gloria M. Petersen, Ann L. Oberg, Brian F. Kabat,
Joshua P. Slusser, Liang Wang, Bruce W. Morlan, Amy J. French, Thomas C. Smyrk,
Noralane M. Lindor, and Stephen N. Thibodeau

.....2323

The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes.

Lisa A. Carey, E. Claire Dees, Lynda Sawyer, Lisa Gatti, Dominic T. Moore, Frances Collichio,
David W. Ollila, Carolyn I. Sartor, Mark L. Graham, and Charles M. Perou

.....2329

ADAM-17 Expression in Breast Cancer Correlates with Variables of Tumor Progression.

Patricia M. McGowan, Brid M. Ryan, Arnold D.K. Hill, Enda McDermott, Niall O'Higgins,
and Michael J. Duffy

.....2335

Reciprocal Regulation of SOCS1 and SOCS3 Enhances Resistance to Ionizing Radiation

in Glioblastoma Multiforme. Hong Zhou, Rika Miki, Mervi Eeva, Francesca M. Fike,
David Seligson, Lu Yang, Akihiko Yoshimura, Michael A. Teitell, Christina A.M. Jamieson,
and Nicholas A. Cacalano

.....2344

Down-Regulation of CD9 Expression during Prostate Carcinoma Progression Is Associated with CD9 mRNA Modifications.

Jia-Chi Wang, Louis R. Bégin, Nathalie G. Bérubé, Simone Chevalier,
Armen G. Aprikian, Henriette Gourdeau, and Mario Chevrette

.....2354

Role of CD14 Promoter Polymorphisms in *Helicobacter pylori* Infection-Related Gastric Carcinoma.

Dan Zhao, Tong Sun, Xuemei Zhang, Yongli Guo, Dianke Yu, Ming Yang, Wen Tan,
Guiqi Wang, and Dongxin Lin

.....2362

c-Kit/PDGFR α Gene Status Alterations Possibly Related to Primary Imatinib Resistance in Gastrointestinal Stromal Tumors.

Francesca Miselli, Paola Casieri, Tiziana Negri, Marta Orsenigo,
M. Stefania Lagonigro, Alessandro Gronchi, Marco Fiore, Paolo G. Casali, Rossella Bertulli,
Antonino Carbone, Marco A. Pierotti, Elena Tamborini, and Silvana Pilotti

.....2369

Imaging, Diagnosis, Prognosis

Predicting Hepatocellular Carcinoma by Detection of Aberrant Promoter Methylation in Serum DNA. Yu-Jing Zhang, Hui-Chen Wu, Jing Shen, Habibul Ahsan, Wei Yann Tsai, Hwai-I Yang, Li-Yu Wang, Shu-Yuan Chen, Chien-Jen Chen, and Regina M. Santella2378

Serum Cytokine Profiling as a Diagnostic and Prognostic Tool in Ovarian Cancer: A Potential Role for Interleukin 7. Annechien J.A. Lambeck, Anne P.G. Crijns, Ninke Leffers, Wim J. Sluiter, Klaske A. ten Hoor, Mike Braid, Ate G.J. van der Zee, Toos Daemen, Hans W. Nijman, and W. Martin Kast2385

Cancer Therapy: Clinical

Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab. Jesús G. Berdeja, Allan Hess, David M. Lucas, Paul O'Donnell, Richard F. Ambinder, Louis F. Diehl, Denise Carter-Brookins, Susan Newton, and Ian W. Flinn2392

Phase II Trials Published in 2002: A Cross-Specialty Comparison Showing Significant Design Differences between Oncology Trials and Other Medical Specialties. Laura C. Michaelis and Mark J. Ratain2400

Multiple Molecular Markers as Predictors of Colorectal Cancer in Patients with Normal Perioperative Serum Carcinoembryonic Antigen Levels. Jaw-Yuan Wang, Shiu-Ru Lin, Deng-Chyang Wu, Chien-Yu Lu, Fang-Jung Yu, Jan-Sing Hsieh, Tian-Lu Cheng, Lok-Beng Koay, and Yih-Huei Uen2406

Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung. Bart P.H. Wittgen, Peter W.A. Kunst, Kasper van der Born, Atie W. van Wijk, Walter Perkins, Frank G. Pilkievicz, Roman Perez-Soler, Susan Nicholson, Godefridus J. Peters, and Pieter E. Postmus2414

Multiplex Analysis of Serum Cytokines in Melanoma Patients Treated with Interferon- α 2b. Zoya R. Yurkovetsky, John M. Kirkwood, Howard D. Edington, Adele M. Marrangoni, Lyudmila Velikokhatnaya, Matthew T. Winans, Elieser Gorelik, and Anna E. Lokshin2422

Cancer Therapy: Preclinical

Cholecystokinin Down-Regulation by RNA Interference Impairs Ewing Tumor Growth. Jaime Carrillo, Eva García-Aragoncillo, Daniel Azorín, Noelia Agra, Ana Sastre, Imelda González-Mediero, Purificación García-Miguel, Ángel Pestaña, Soledad Gallego, Dolores Segura, and Javier Alonso2429

Silencing of Hypoxia Inducible Factor-1 α by RNA Interference Attenuates Human Glioma Cell Growth *In vivo*. David L. Gillespie, Kum Whang, Brian T. Ragel, Jeannette R. Flynn, David A. Kelly, and Randy L. Jensen2441

***In vivo* Imaging of Oral Mucositis in an Animal Model Using Optical Coherence Tomography and Optical Doppler Tomography.** Petra Wilder-Smith, Marie J. Hammer-Wilson, Jun Zhang, Qiang Wang, Kathryn Osann, Zhongping Chen, Harvey Wigdor, Joel Schwartz, and Joel Epstein2449

A Novel Chromogranin-A Promoter-Driven Oncolytic Adenovirus for Midgut Carcinoid Therapy. Justyna Leja, Helena Dzojic, Elisabet Gustafson, Kjell Öberg, Valeria Giandomenico, and Magnus Essand2455

The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2. Weiguo Liu, Maria R. Baer, Mary Jo Bowman, Paula Pera, Xiang Zheng, Janet Morgan, Ravindra A. Pandey, and Allan R. Oseroff2463

The Human T-Box Mesodermal Transcription Factor Brachyury Is a Candidate Target for T-Cell-Mediated Cancer Immunotherapy. Claudia Palena, Dmitry E. Plev, Kwong Y. Tsang, Romaine I. Fernando, Mary Litzinger, Larisa L. Krukovskaya, Ancha V. Baranova, Andrei P. Kozlov, and Jeffrey Schlom2471

HLA-DQB1*02-Restricted HPV-16 E7 Peptide-Specific CD4⁺ T-Cell Immune Responses Correlate with Regression of HPV-16-Associated High-Grade Squamous Intraepithelial Lesions. Shiwen Peng, Cornelia Trimble, Lee Wu, Drew Pardoll, Richard Roden, Chien-Fu Hung, and T.-C. Wu.....2479

Activated Pregnenolone X-Receptor Is a Target for Ketoconazole and Its Analogs. Hongwei Wang, Haiyan Huang, Hao Li, Denise G. Teotico, Michael Sinz, Sharyn D. Baker, Jeffrey Staudinger, Ganjam Kalpana, Matthew R. Redinbo, and Sridhar Mani2488

Proteomics of Canine Lymphoma Identifies Potential Cancer-Specific Protein Markers. Dudley L. McCaw, Arvan S. Chan, Andrew L. Stegner, Brian Mooney, Jeffrey N. Bryan, Susan E. Turnquist, Carolyn J. Henry, Hannah Alexander, and Stephen Alexander2496

Characterization and Magnetic Resonance Imaging of a Rat Model of Human B-Cell Central Nervous System Lymphoma. Carole Soussain, Leslie L. Muldoon, Csanad Varallyay, Kristoph Jahnke, Luciana De Paula, and Edward A. Neuwelt2504

Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy *In vivo*. Felix Y. Feng, Carlos A. Lopez, Daniel P. Normolle, Sooryanarayana Varambally, Xiaoxin Li, Patrick Y. Chun, Mary A. Davis, Theodore S. Lawrence, and Mukesh K. Nyati2512


Cancer Prevention

Ursodeoxycholic Acid versus Sulfasalazine in Colitis-Related Colon Carcinogenesis in Mice. Hiroyuki Kohno, Rikako Suzuki, Yumiko Yasui, Shingo Miyamoto, Keiji Wakabayashi, and Takuji Tanaka2519

Polymorphisms of MTHFD, Plasma Homocysteine Levels, and Risk of Gastric Cancer in a High-Risk Chinese Population. Lina Wang, Qiao Ke, Wensen Chen, Jianming Wang, Yongfei Tan, Yan Zhou, Zhaolai Hua, Weiliang Ding, Juying Niu, Jing Shen, Zuofeng Zhang, Xinru Wang, Yaochu Xu, and Hongbing Shen.....2526

About the Cover

Activated EGFR (*red*) and Ki67 (*green*) were expressed abundantly in head and neck carcinoma xenografts developed in nude mice. Cetuximab treatment caused more prolonged inhibition of EGFR, its downstream effectors STAT3 and Bcl_{XL}, and the proliferation marker Ki67 compared with treatment with gefitinib. This resulted in a more potent tumor response to cetuximab compared with gefitinib in this model system. For further details, please see Feng *et al.* on page 2512 in this issue.



Clinical Cancer Research

13 (8)

Clin Cancer Res 2007;13:2307-2532.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/13/8>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/13/8>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.